Promise Bio
The AI engine Fit Assessment
BetaThe company effectively leverages machine learning for biomarker discovery and therapeutic expansion, demonstrating a strong fit in the healthcare innovation space.
Blurb
Promise Bio utilizes AI to analyze epiproteomics for autoimmune diseases.
HQ Location
Tel Aviv-Yafo (Israel)
Founded
2023
Employees
1 - 10
Total funding raised
$8.30M
Last Funding Event
Grant, December 16, 2024
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Biomarker Identification
Promise Bio is focused on pioneering precision medicine by utilizing epiproteomic analysis to understand autoimmune diseases. The company employs a cloud-based AI platform to perform comprehensive analyses of standard mass-spectrometry data, revealing insights into protein modifications that affect disease mechanisms.